New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 23, 2014
10:55 EDTAMGN, AMGN, NVS, NVS, MRK, MRK, INCY, INCY, GSK, GSK, EXEL, EXEL, BMY, BMY, AZN, AZN, ARRY, ARRY, RHHBY, RHHBYLeerink's pharma and biotech analysts hold an analyst/industry conference call
Biotech and Pharmaceuticals Analysts Liang and Kapur discuss the market opportunity and role of immunotherapy in the adjuvant melanoma setting ahead of the upcoming ASCO Annual Meeting on an Analyst/Industry conference call. Relevant companies AMGN, ARRY, AZN, BMY, EXEL, GSK, INCY, MRK, NVS and RHHBY may be discussed on the Analyst/Industry conference call to be held on May 28 at 11:30 am.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 >>
November 16, 2015
09:19 EDTARRYOn The Fly: Pre-market Movers
HIGHER: Nexvet Biopharma (NVET), up 16.8% after NV-01 study meets primary endpoint... Protalix BioTherapeutics (PLX), up 4.8% after announcing that it will conduct a Phase III clinical trial for PRX-102... Array Biopharma (ARRY), up 4.3% after announcing a commercialization collaboration with Pierre Fabre... Perrigo (PRGO), up 2.1% after being upgraded to Buy from Neutral at UBS. DOWN AFTER EARNINGS: Dillard's (DDS), down 11.7% after reporting quarterly results. ALSO LOWER: Clovis Oncology (CLVS), down 71.3% after the FDA requested additional clinical data for rociletinib... KaloBios Pharmaceuticals (KBIO), down 48.9% after announcing that it will wind down its operations... Starwood Hotels (HOT), down 6.3% after announcing that Marriott (MAR) will acquire the company... Marriott is down 2.4%... Five Below (FIVE), down 3.1% after being downgraded to Hold from Buy at Deutsche Bank.
08:35 EDTMRKMerck to present Phase 2 hep C therapy data at The Liver Meeting
Subscribe for More Information
08:32 EDTAZNClovis reopens, down 64% after FDA requests added data for rociletinib
AstraZeneca (AZN), which is at work on a drug similar to rociletinib, is up 2.5% in pre-market trading.
08:19 EDTARRYArray BioPharma to hold a conference call
Management announces Array BioPharma and Pierre Fabre will collaborate to globally develop and commercialize Array's two novel oncology products, Binimetinib and Encorafenib, on a conference call to be held on November 16 at 9 am. Webcast Link
07:36 EDTARRYArray BioPharma and Pierre Fabre announce commercialization collaboration
Subscribe for More Information
07:24 EDTMRKSalomon to hold a conference
Subscribe for More Information
07:00 EDTBMYBristol-Myers announces data from Phase 3 ALLY-3+ trial for Daklinza
Bristol-Myers announced late-breaking data from the Phase 3 ALLY-3+ trial investigating a regimen of Daklinza in combination with sofosbuvir and ribavirin in genotype 3 hepatitis C patients with advanced fibrosis or cirrhosis, for treatment durations of 12 and 16 weeks. This patient population is one of the most difficult to treat, among whom sustained virologic response rates, or cure, have proved harder to achieve. The results show that 100% of patients in the advanced fibrosis cohort achieved SVR12 in both the 12- and 16-week arms of the study. SVR12 rates were 83% and 89% in patients with cirrhosis in the 12- and 16-week arms, respectively.
05:57 EDTAZNAstraZeneca urges UK for antibiotics investment shake-up, Financial Time says
AstraZeneca has urged the U.K. government to develop a new model for incentivizing investment in antibiotics, reports the Financial Times. In a letter to the Financial Times, the company said it has joined other "leading voices" in the life sciences sectory to implore Britain to go ahead with a new system rather than waiting for an international agreement. The company said a new payment model was needed that would reward companies' investments but without encouraging the over-use of antibiotics. Reference Link
November 15, 2015
15:19 EDTMRKMerck reports integrated analysis of six trials of elbasvir/grazoprevir
Subscribe for More Information
15:15 EDTMRKMerck reports Phase 3 data on elbasvir/grazoprevir in patients injecting drugs
Subscribe for More Information
November 13, 2015
10:18 EDTRHHBYRoche receives FDA approval for cobas EGFR mutation test
Subscribe for More Information
10:16 EDTINCYOptions with decreasing implied volatility
Subscribe for More Information
09:37 EDTAZNClovis down 3% after FDA approves AstraZeneca lung cancer drug
Subscribe for More Information
09:34 EDTAZN, RHHBYFDA approves Roche's cobas EGFR Mutation Test
Subscribe for More Information
09:31 EDTAZNFDA approves AstraZeneca non-small cell lung cancer treatment
Subscribe for More Information
08:02 EDTMRKMerck: DMC recommends anacetrapib study continue with no changes
Subscribe for More Information
November 12, 2015
17:02 EDTMRKMerck Animal Health to Acquire Harrisvaccines
Merck Animal Health and Harrisvaccines announced the companies have entered into an agreement under which Merck Animal Health will acquire Harrisvaccines, a privately-held company that develops, manufactures and sells vaccines for food production and companion animals. The terms of the agreement were not disclosed. The companies expect the transaction to close in the fourth quarter of 2015.
11:50 EDTRHHBYRoche to restructure manufacturing network for small molecules
Subscribe for More Information
11:50 EDTMRKMerck issues statement regarding CUBICIN patent litigation
Merck issued the following statement regarding the decision of the U.S. Court of Appeals for the Federal Circuit: "The decision validated the patent for CUBICIN that expires on June 15, 2016, but invalidated four patents with expiration dates in 2019 and 2020. The company is reviewing the decision and is considering its next steps, which may include seeking further review at the Federal Circuit or Supreme Court."
08:12 EDTINCYIncyte price target raised to $135 from $130 at Leerink
Subscribe for More Information
1 | 2 | 3 | 4 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use